nurix therapeutics inc - NRIX
NRIX
Close Chg Chg %
15.95 0.90 5.64%
Closed Market
16.85
+0.90 (5.64%)
Volume: 836.54K
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: nurix therapeutics inc - NRIX
NRIX Key Data
| Open $16.29 | Day Range 16.28 - 17.01 |
| 52 Week Range 8.18 - 22.50 | Market Cap $1.70B |
| Shares Outstanding 102.84M | Public Float 101.21M |
| Beta 1.96 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.04 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.25M |
NRIX Performance
| 1 Week | 2.00% | ||
| 1 Month | -12.69% | ||
| 3 Months | 36.88% | ||
| 1 Year | -10.75% | ||
| 5 Years | -56.55% |
NRIX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
About nurix therapeutics inc - NRIX
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.
NRIX At a Glance
Nurix Therapeutics, Inc.
1600 Sierra Point Parkway
Brisbane, California 94158
| Phone | 1-415-660-5320 | Revenue | 83.98M | |
| Industry | Biotechnology | Net Income | -264,457,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 53.953% | |
| Fiscal Year-end | 11 / 2026 | Employees | 317 | |
| View SEC Filings |
NRIX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 18.246 |
| Price to Book Ratio | 3.341 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.729 |
| Enterprise Value to Sales | 11.849 |
| Total Debt to Enterprise Value | 0.056 |
NRIX Efficiency
| Revenue/Employee | 264,921.136 |
| Income Per Employee | -834,249.211 |
| Receivables Turnover | 55.987 |
| Total Asset Turnover | 0.122 |
NRIX Liquidity
| Current Ratio | 7.018 |
| Quick Ratio | 7.018 |
| Cash Ratio | 6.857 |
NRIX Profitability
| Gross Margin | 77.547 |
| Operating Margin | -340.16 |
| Pretax Margin | -314.00 |
| Net Margin | -314.905 |
| Return on Assets | -38.383 |
| Return on Equity | -49.629 |
| Return on Total Capital | -44.486 |
| Return on Invested Capital | -46.439 |
NRIX Capital Structure
| Total Debt to Total Equity | 10.344 |
| Total Debt to Total Capital | 9.375 |
| Total Debt to Total Assets | 7.932 |
| Long-Term Debt to Equity | 9.82 |
| Long-Term Debt to Total Capital | 8.90 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Nurix Therapeutics Inc - NRIX
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 38.63M | 76.99M | 54.55M | 83.98M | |
Sales Growth
| +29.84% | +99.31% | -29.15% | +53.95% | |
Cost of Goods Sold (COGS) incl D&A
| 10.81M | 13.65M | 16.43M | 18.86M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 10.81M | 13.65M | 16.43M | 18.86M | |
Depreciation
| 10.81M | 13.65M | 16.43M | 18.86M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +77.70% | +26.33% | +20.32% | +14.78% | |
Gross Income
| 27.82M | 63.33M | 38.12M | 65.12M | |
Gross Income Growth
| +17.54% | +127.66% | -39.81% | +70.83% | |
Gross Profit Margin
| +72.02% | +82.26% | +69.88% | +77.55% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 211.69M | 218.40M | 251.15M | 350.79M | |
Research & Development
| 179.15M | 181.62M | 212.31M | 308.16M | |
Other SG&A
| 32.54M | 36.78M | 38.83M | 42.63M | |
SGA Growth
| +49.54% | +3.17% | +15.00% | +39.67% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (183.87M) | (155.06M) | (213.03M) | (285.67M) | |
Non Operating Income/Expense
| 3.51M | 11.12M | 19.73M | 21.97M | |
Non-Operating Interest Income
| 3.51M | 11.12M | 19.73M | 21.97M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (180.36M) | (143.95M) | (193.30M) | (263.70M) | |
Pretax Income Growth
| -54.07% | +20.19% | -34.28% | -36.42% | |
Pretax Margin
| -466.93% | -186.98% | -354.36% | -314.00% | |
Income Tax
| - | - | 270.00K | 760.00K | - |
Income Tax - Current - Domestic
| - | - | - | 760.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | 270.00K | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (180.36M) | (143.95M) | (193.57M) | (264.46M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (180.36M) | (143.95M) | (193.57M) | (264.46M) | |
Net Income Growth
| -53.90% | +20.19% | -34.47% | -36.62% | |
Net Margin Growth
| -466.93% | -186.98% | -354.85% | -314.90% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (180.36M) | (143.95M) | (193.57M) | (264.46M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (180.36M) | (143.95M) | (193.57M) | (264.46M) | |
EPS (Basic)
| -3.7105 | -2.6491 | -2.8839 | -3.0514 | |
EPS (Basic) Growth
| -35.81% | +28.61% | -8.86% | -5.81% | |
Basic Shares Outstanding
| 48.61M | 54.34M | 67.12M | 86.67M | |
EPS (Diluted)
| -3.7105 | -2.6491 | -2.8839 | -3.0514 | |
EPS (Diluted) Growth
| -35.81% | +28.61% | -8.86% | -5.81% | |
Diluted Shares Outstanding
| 48.61M | 54.34M | 67.12M | 86.67M | |
EBITDA
| (173.06M) | (141.41M) | (196.60M) | (266.81M) | |
EBITDA Growth
| -54.79% | +18.29% | -39.03% | -35.71% | |
EBITDA Margin
| -448.03% | -183.68% | -360.41% | -317.71% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 30.00 | |
| Number of Ratings | 17 | Current Quarters Estimate | -0.765 | |
| FY Report Date | 02 / 2026 | Current Year's Estimate | -3.137 | |
| Last Quarter’s Earnings | -0.82 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.05 | Next Fiscal Year Estimate | -2.993 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 15 | 15 | 16 | 14 |
| Mean Estimate | -0.77 | -0.77 | -3.14 | -2.99 |
| High Estimates | -0.65 | -0.48 | -2.64 | -2.07 |
| Low Estimate | -0.89 | -0.93 | -3.71 | -3.57 |
| Coefficient of Variance | -9.18 | -14.50 | -9.79 | -13.77 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 16 | 16 | 15 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 0 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Nurix Therapeutics Inc - NRIX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Nurix Therapeutics Inc - NRIX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 2, 2025 | Hans van Houte Chief Financial Officer | 42,360 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Gwenn M. Hansen Chief Scientific Officer | 8,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Gwenn M. Hansen Chief Scientific Officer | 9,621 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Gwenn M. Hansen Chief Scientific Officer | 61,516 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.5 per share | 707,434.00 |
| May 2, 2025 | Gwenn M. Hansen Chief Scientific Officer | 64,893 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Gwenn M. Hansen Chief Scientific Officer | 61,143 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Gwenn M. Hansen Chief Scientific Officer | 59,143 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Hans van Houte Chief Financial Officer | 30,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Hans van Houte Chief Financial Officer | 8,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Hans van Houte Chief Financial Officer | 8,659 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Hans van Houte Chief Financial Officer | 39,922 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.5 per share | 459,103.00 |
| May 2, 2025 | Gwenn M. Hansen Chief Scientific Officer | 30,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Hans van Houte Chief Financial Officer | 38,610 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Hans van Houte Chief Financial Officer | 36,610 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Christine Ring Chief Legal Officer | 30,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Christine Ring Chief Legal Officer | 8,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Christine Ring Chief Legal Officer | 5,773 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Christine Ring Chief Legal Officer | 37,318 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.5 per share | 429,157.00 |
| May 2, 2025 | Christine Ring Chief Legal Officer | 40,212 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 2, 2025 | Christine Ring Chief Legal Officer | 36,462 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |